文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

Medicare患者外用免疫调节剂费用因处方医生专科而异

The cost of topical immunomodulator therapy in Medicare patients varies by prescriber specialty.
PubMed 文献 · J Am Acad Dermatol · 2017-02-02

基于2008和2010年Medicare处方药公共使用档案的横断面研究,比较不同专科医生开具外用免疫调节剂(TI)的费用差异。结果显示品牌药每30天供应比仿制药平均贵174.02美元(P<.001),专科医生(主要为皮肤科)处方总费用比家庭医学和内科医生高7.36-14.57美元,患者自付费用高1.69-3.16美元(P<.01),专科医生品牌药处方率为8%而非专科医生为1.4%-3.1%。

要点

  • 品牌药比仿制药每30天供应平均贵174.02美元(P<.001)
  • 专科医生处方总费用比家庭医学和内科医生高7.36-14.57美元,患者自付高1.69-3.16美元(P<.01)
  • 专科医生品牌药处方率8%,非专科医生为1.4%-3.1%

核心结论

  • 专科医生(主要为皮肤科)开具的外用免疫调节剂费用高于初级保健医生,可通过在相应效力类别中选择更多仿制药来降低费用。

研究设计与样本

  • 横断面研究,使用2008年和2010年Centers for Medicare & Medicaid Services处方药公共使用档案,包含Medicare受益人100%的药物索赔数据。

主要发现

  • 品牌药每30天供应平均比仿制药贵174.02美元(P<.001)。
  • 健康保险福利阶段、药物选择、品牌名称和覆盖类型是患者费用的最大决定因素(P<.001)。
  • 专科医生(主要为皮肤科)开具的低、中、高效力外用免疫调节剂处方费用高于家庭医学、内科和精神科/神经科医生。
  • 专科医生30天供应总费用与家庭医学和内科医生相差7.36-14.57美元,患者费用高1.69-3.16美元(P<.01)。
  • 专科医生品牌药处方率为8%,非专科医生为1.4%-3.1%。

临床怎么用

  • 在相应效力类别中选择更多仿制药可能降低外用免疫调节剂费用。

局限性

  • 无法调整某些费用混杂因素,如药物重量或治疗体表面积,数据未反映既往治疗失败或非Medicare患者使用情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topical immunomodulators (TI)-including corticosteroids, calcineurin inhibitors, and vitamin D analogues-are commonly prescribed in multiple specialties, but cost comparisons are lacking. OBJECTIVE: To evaluate differences in costs of TI across specialties and determine associated variables. METHODS: A cross-sectional study was performed using the Centers for Medicare & Medicaid Services 2008 and 2010 Prescription Drug Public Use Profiles, which contain 100% of drug claims made by Medicare beneficiaries. RESULTS: Branded drugs cost an average of $174.02 more than generics per 30-day supply (P < .001). Differences in health insurance benefit phase, drug choice, brand name, and coverage type were the greatest determinants of patient cost (P < .001). Prescriptions for low-, medium-, and high-potency TI from specialists (mostly dermatologists) cost more than those from family medicine, internal medicine, and psychiatry/neurology physicians; total costs of a 30-day supply from a specialist differed from family and internal medicine physicians by $7.36-$14.57, and patient costs were higher for specialists by $1.69-$3.16 (P < .01). Brand names were prescribed 8% of the time by specialists and 1.4%-3.1% by nonspecialists. LIMITATIONS: We were unable to adjust for some confounders of cost, such as medication weight or treated body area, and the data does not reflect previous treatment failures or use by non-Medicare patients. CONCLUSION: The costs of TIs prescribed by specialists (primarily dermatologists) are higher than those prescribed by primary care physicians and could be reduced by choosing more generics within the respective potency classes.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Zhang M, Silverberg JI, Kaffenberger BH, et al. The cost of topical immunomodulator therapy in Medicare patients varies by prescriber specialty. J Am Acad Dermatol. 2017. PMID: 28162853. doi:10.1016/j.jaad.2016.11.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。